Loading organizations...
Adnexus Therapeutics is a Waltham, Massachusetts-based biotechnology enterprise that discovers and develops a proprietary class of targeted engineered protein biologics known as Adnectins for oncology applications. The organization operated with approximately 50 employees before being acquired by pharmaceutical giant Bristol-Myers Squibb for $430 million in upfront payments and up to $75 million in milestone disbursements. Prior to this acquisition, the company secured venture capital backing from prominent life science investors including Flagship Pioneering, Polaris Venture Partners, Atlas Venture, and Venrock. The firm's core research platform focuses on designing specialized protein therapeutics that target specific disease biology in ways that traditional antibodies cannot effectively address. Following the transaction, the proprietary technology was integrated directly into the parent company's broader clinical research and biopharmaceutical pipeline. Adnexus was originally founded as Compound Therapeutics in 2002 by Noubar Afeyan.
Adnexus has raised $56.0M across 3 funding rounds.
Adnexus has raised $56.0M in total across 3 funding rounds.
Adnexus Biotechnologies Inc. is a Texas-based biotech company specializing in AI-driven drug discovery and development of proprietary monoclonal antibodies and proteins for treating infectious diseases, including HIV, SARS-CoV-2, and Monkeypox.[1][5][6] It serves patients, healthcare providers, and researchers by addressing unmet needs in antiviral therapies through its Sutra™ AI platform, which analyzes vast datasets from 19 viruses, 8 million molecules, and 200,000 human microbiome samples to identify conserved viral targets, design universal antibodies, and enable personalized medicine.[3][5][6] The company solves critical problems like virus mutations and escape by producing fully human, broadly neutralizing antibodies with low immunogenicity risk, while also advancing diagnostics, vaccines, and botanicals via platforms like NatureScript and Adnexus One.[1][5] Growth momentum includes rapid identification of Monkeypox targets within a week of WHO's emergency declaration, HIV targets stable for 30 years, a strategic LOI with 1606 Corp for investment, and plans for SAAS/DAAS revenue models.[1][6]
Adnexus emerged from innovative biotech research leveraging human immune responses, led by Dr. Gaurav Chandra, its CEO and recognized expert in antiviral treatments.[1][6] Operating from a lab at the University of Missouri, the company developed its core Sutra™ AI platform to merge biology and technology, starting with human "immune-B cells" from recovered patients to create species-specific monoclonal antibodies for humans and animals.[1][5][6] Pivotal early traction came from AI-powered breakthroughs: identifying immutable SARS-CoV-2 targets as the first in its class and Monkeypox targets in record time during the 2022 global emergency, building on 30 years of stable HIV targets.[1] Chandra's vision evolved the focus from antibody production to a comprehensive AI ecosystem for drug discovery, repurposing, genomics, and personalized therapies, culminating in recent unveils of Sutra™ and partnerships like the LOI with 1606 Corp.[3][6] Note: This distinguishes it from the unrelated Adnexus Therapeutics, acquired in 2007 after focusing on AdNectins.[4]
Adnexus rides the AI-biotech convergence wave, accelerating drug discovery amid rising antimicrobial resistance, pandemics, and demand for personalized medicine—trends amplified by post-COVID innovation needs.[3][6] Its timing aligns with AI advancements like structure prediction, enabling faster, cheaper development versus conventional trials, while market forces favor scalable platforms amid $100B+ annual infectious disease burdens.[5][6] By open-sourcing expertise via SAAS/DAAS and focusing on universal antibodies, Adnexus influences the ecosystem: empowering startups/academics, predicting outbreaks, and bridging human-animal health under One Health, potentially reducing global therapy development timelines from years to months.[1][6]
Adnexus is poised to scale via Sutra™ commercialization, HIV therapeutic advancements, and revenue diversification into SAAS/DAAS by 2026, bolstered by investments like the 1606 Corp LOI.[6] Evolving AI models and expanding datasets will shape its path, targeting neurodegenerative diseases and novel pandemics while personalizing care to minimize side effects.[3][6] Its influence may grow as a biotech enabler, licensing IP and fostering collaborations that democratize AI-drug tools—ultimately transforming Adnexus from antibody pioneer to ecosystem leader in biology-tech fusion, curing infectious threats at scale.[1][5]
Adnexus has raised $56.0M in total across 3 funding rounds.
Adnexus's investors include Acorn Bioventures, Flagship Ventures, Polaris Partners.
Adnexus has raised $56.0M across 3 funding rounds. Most recently, it raised $16.0M Series C in August 2007.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 19, 2024 | Kamae | $1.5M Seed | — | Auriga Cyber Ventures, LA Financiere DE L'intendance, Super Capital, VIF |
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2007 | $16M Series C | — | Acorn Bioventures, Flagship Ventures, Polaris Partners | Announced |
| Jun 1, 2006 | $27M Series B | — | Acorn Bioventures, Flagship Ventures, Polaris Partners | Announced |
| Feb 1, 2003 | $13M Series A | — | Flagship Ventures, Polaris Partners | Announced |
